Emerald Mutual Fund Advisers Trust Decreased Its Assembly Biosciences (ASMB) Stake; Lagoda Investment Management LP Lowered By $10.11 Million Its Seattle Genetics (SGEN) Position

June 13, 2018 - By mmahotstuff

Seattle Genetics, Inc. (NASDAQ:SGEN) Logo

Lagoda Investment Management Lp decreased Seattle Genetics Inc (SGEN) stake by 63.42% reported in 2018Q1 SEC filing. Lagoda Investment Management Lp sold 194,429 shares as Seattle Genetics Inc (SGEN)’s stock declined 0.23%. The Lagoda Investment Management Lp holds 112,147 shares with $5.87 million value, down from 306,576 last quarter. Seattle Genetics Inc now has $10.95 billion valuation. The stock increased 3.70% or $2.47 during the last trading session, reaching $69.21. About 1.23 million shares traded or 31.23% up from the average. Seattle Genetics, Inc. (NASDAQ:SGEN) has declined 15.50% since June 13, 2017 and is downtrending. It has underperformed by 28.07% the S&P500. Some Historical SGEN News: ; 09/03/2018 – News On Cascadian Therapeutics Inc. (CASC) Now Under SGEN; 20/03/2018 – SEATTLE GENETICS: FDA APPROVES EXPANDED USE FOR ADCETRIS; 26/04/2018 – SEATTLE GENETICS INC – SEES 2018 NON-CASH COSTS $95 MLN TO $105 MLN; 26/04/2018 – SEATTLE GENETICS INC – SEES 2018 RESEARCH AND DEVELOPMENT (R&D) $530 MLN TO $580 MLN; 19/04/2018 – DJ Seattle Genetics Inc, Inst Holders, 1Q 2018 (SGEN); 12/04/2018 – Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American; 10/04/2018 – Biotech group Genmab aims to own bigger share of new drug pipeline; 16/04/2018 – CELLDEX THERAPEUTICS INC – GLEMBATUMUMAB VEDOTIN SAFETY PROFILE WAS CONSISTENT WITH PRIOR EXPERIENCE; 09/03/2018 – SEATTLE GENETICS: CASCADIAN THERAPEUTICS TENDER OFFER COMPLETE; 07/03/2018 – SEATTLE GENETICS STARTS NEW PHASE 1 STUDY

Emerald Mutual Fund Advisers Trust decreased Assembly Biosciences Inc (ASMB) stake by 27.98% reported in 2018Q1 SEC filing. Emerald Mutual Fund Advisers Trust sold 43,034 shares as Assembly Biosciences Inc (ASMB)’s stock declined 24.71%. The Emerald Mutual Fund Advisers Trust holds 110,748 shares with $5.44 million value, down from 153,782 last quarter. Assembly Biosciences Inc now has $932.39M valuation. The stock increased 3.68% or $1.61 during the last trading session, reaching $45.37. About 132,302 shares traded. Assembly Biosciences, Inc. (NASDAQ:ASMB) has risen 70.43% since June 13, 2017 and is uptrending. It has outperformed by 57.86% the S&P500. Some Historical ASMB News: ; 12/04/2018 – Assembly Biosciences Presents Positive Interim Data from Phase 1a and 1b Studies of ABI-H0731 in HBV Patients in a Late-Breaker Session at the EASL Conference; 12/03/2018 – Assembly Biosciences Appoints Graham Cooper as Chief Financial Officer and Operating Chief; 20/04/2018 – DJ Assembly Biosciences Inc, Inst Holders, 1Q 2018 (ASMB); 29/05/2018 – Factors of Influence in 2018, Key Indicators and Opportunity within Assembly Biosciences, MGP Ingredients, Globant S.A, 8point3; 12/03/2018 Assembly Biosciences Announces Additions to Management Team and Board of Directors; 12/03/2018 – Assembly Biosciences Appoints Helen S. Kim to Board of Directors; 12/04/2018 – Assembly Biosciences: Robust Antiviral Activity Observed in Hepatitis B Virus Patients From Positive Interim Data From Phase 1a and 1b Studies of ABI-H0731; 28/03/2018 – Assembly Biosciences Announces ABI-H0731 Phase 1b Interim Data Accepted as a Late-Breaker Poster at The International Liver Con; 02/04/2018 – Assembly Biosciences Appoints Jackie Papkoff, PhD, Senior Vice President, Chief Scientific Officer Microbiome; 28/03/2018 – Assembly Biosciences Announces ABI-H0731 Phase 1b Interim Data Accepted as a Late-Breaker Poster at The International Liver Congress™ (EASL)

Among 5 analysts covering Assembly Biosciences (NASDAQ:ASMB), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Assembly Biosciences had 7 analyst reports since November 8, 2017 according to SRatingsIntel. The rating was maintained by FBR Capital on Friday, March 9 with “Hold”. As per Tuesday, May 8, the company rating was maintained by FBR Capital. The stock has “Neutral” rating by Chardan Capital Markets on Friday, April 13.

Analysts await Assembly Biosciences, Inc. (NASDAQ:ASMB) to report earnings on August, 8. After $-0.80 actual earnings per share reported by Assembly Biosciences, Inc. for the previous quarter, Wall Street now forecasts 12.50% negative EPS growth.

More important recent Assembly Biosciences, Inc. (NASDAQ:ASMB) news were published by: Nasdaq.com which released: “Assembly Biosciences to Host Research and Development Day on Wednesday, June 20, 2018” on June 13, 2018, also Benzinga.com published article titled: “36 Biggest Movers From Friday”, Nasdaq.com published: “Assembly Biosciences Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” on June 08, 2018. More interesting news about Assembly Biosciences, Inc. (NASDAQ:ASMB) was released by: Globenewswire.com and their article: “Factors of Influence in 2018, Key Indicators and Opportunity within Assembly Biosciences, MGP Ingredients, Globant …” with publication date: May 29, 2018.

Emerald Mutual Fund Advisers Trust increased Catalyst Pharmaceutical Partners (NASDAQ:CPRX) stake by 231,328 shares to 938,078 valued at $2.24M in 2018Q1. It also upped Triumph Bancorp stake by 116,096 shares and now owns 255,706 shares. Byline Bancorp Inc was raised too.

Investors sentiment increased to 1.61 in Q1 2018. Its up 0.38, from 1.23 in 2017Q4. It is positive, as 24 investors sold SGEN shares while 53 reduced holdings. 31 funds opened positions while 93 raised stakes. 159.52 million shares or 12.47% more from 141.83 million shares in 2017Q4 were reported. Capital International Sarl reported 191,000 shares stake. The Massachusetts-based Geode Cap Mngmt Ltd Llc has invested 0.02% in Seattle Genetics, Inc. (NASDAQ:SGEN). State Street Corp, a Massachusetts-based fund reported 3.14M shares. Raymond James And Assocs holds 0% or 9,220 shares. Kbc Nv stated it has 10,968 shares. Advisors Asset Management accumulated 13,584 shares. Aperio Group Ltd Limited Liability Company holds 26,562 shares. Renaissance Tech Limited Liability holds 0.01% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 239,313 shares. Capital Guardian Tru holds 1.01% in Seattle Genetics, Inc. (NASDAQ:SGEN) or 1.37M shares. Citadel Advsrs Limited Liability Company owns 0.03% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 958,665 shares. The Massachusetts-based Panagora Asset Management has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Bancorp Of Montreal Can reported 0% stake. Platinum Invest Management Ltd owns 40,500 shares. New York-based Morgan Stanley has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Public Employees Retirement Association Of Colorado stated it has 0.01% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN).

Analysts await Seattle Genetics, Inc. (NASDAQ:SGEN) to report earnings on July, 26. They expect $-0.34 earnings per share, up 12.82% or $0.05 from last year’s $-0.39 per share. After $-0.61 actual earnings per share reported by Seattle Genetics, Inc. for the previous quarter, Wall Street now forecasts -44.26% EPS growth.

Lagoda Investment Management Lp increased Berkshire Hathaway Inc Del (BRKA) stake by 40 shares to 42 valued at $12.56M in 2018Q1. It also upped Regeneron Pharmaceuticals (NASDAQ:REGN) stake by 2,282 shares and now owns 66,660 shares. Berkshire Hathaway Inc Del (BRKB) was raised too.

Among 18 analysts covering Seattle Genetics (NASDAQ:SGEN), 10 have Buy rating, 0 Sell and 8 Hold. Therefore 56% are positive. Seattle Genetics had 68 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Thursday, July 27 by Cowen & Co. SunTrust maintained the stock with “Hold” rating in Wednesday, February 7 report. On Monday, June 11 the stock rating was upgraded by SunTrust to “Buy”. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Buy” rating given on Monday, October 23 by Needham. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Buy” rating given on Friday, September 15 by Needham. The firm has “Hold” rating by Cowen & Co given on Tuesday, June 6. Cantor Fitzgerald downgraded Seattle Genetics, Inc. (NASDAQ:SGEN) on Wednesday, July 27 to “Hold” rating. The rating was maintained by Piper Jaffray on Friday, October 27 with “Hold”. Oppenheimer maintained Seattle Genetics, Inc. (NASDAQ:SGEN) on Monday, June 26 with “Hold” rating. The firm has “Hold” rating given on Monday, July 24 by Oppenheimer.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>